跳至主要内容
临床试验/EUCTR2019-004813-15-BE
EUCTR2019-004813-15-BE进行中(未招募)1 期

Serum concentrations of ropivacaine after unilateral pectoral nerve block type II (Pecs II) in breast cancer surgery - Pecs Serum 2020

AZ Turnhout0 个研究点目标入组 20 人开始时间: 2020年9月7日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria: (1) Age 18 or older (2) BMI between 17 and 35kg/m2, (3) scheduled for elective unilateral mastectomy or tumorectomy with sentinel node resection or axillary clearance, and (4) written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • Patients with (1)known allergies or sensitivity to local anaesthesia, or with (2) a BMI less than 17 or more than 35 kg/m2, (3) who are pregnant, (4) who have renal (GFR < 60ml/min) and/or hepatic impairment (end-stage liver disease that compromises normal hepatic drug metabolism) will be excluded. Given our inclusion and exclusion criteria, minors and subjects not capable of giving informed consent will be excluded from participation in the study.

研究者

发起方
AZ Turnhout

相似试验